Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes

BACKGROUND: In studying the therapeutic evidence of innovative drug treatments, increasing attention is being devoted to differentiating between results that indicate no significant differences among the treatments under examination (“no proof of difference”) and results that demonstrate the therape...

Descripción completa

Detalles Bibliográficos
Autores principales: Messori, Andrea, Fadda, Valeria, Maratea, Dario, Trippoli, Sabrina, Marinai, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065299/
https://www.ncbi.nlm.nih.gov/pubmed/24793219
http://dx.doi.org/10.1007/s13300-014-0066-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065299/
https://www.ncbi.nlm.nih.gov/pubmed/24793219
http://dx.doi.org/10.1007/s13300-014-0066-y

Ejemplares similares